Relay Therapeutics (RLAY) to Release Quarterly Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Relay Therapeutics Price Performance

Shares of NASDAQ RLAY opened at $9.16 on Wednesday. The stock’s fifty day moving average price is $8.20 and its two-hundred day moving average price is $6.44. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -5.23 and a beta of 1.59. Relay Therapeutics has a one year low of $1.77 and a one year high of $9.54.

Insider Buying and Selling at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 13,820 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the completion of the transaction, the chief financial officer directly owned 250,996 shares of the company’s stock, valued at $1,912,589.52. This represents a 5.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter Rahmer sold 11,684 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $89,032.08. Following the transaction, the insider owned 277,964 shares of the company’s stock, valued at $2,118,085.68. The trade was a 4.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 93,302 shares of company stock worth $724,355. 4.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Abel Hall LLC increased its stake in shares of Relay Therapeutics by 16.2% in the fourth quarter. Abel Hall LLC now owns 12,984 shares of the company’s stock worth $110,000 after purchasing an additional 1,809 shares in the last quarter. Cresset Asset Management LLC boosted its holdings in Relay Therapeutics by 5.0% in the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock worth $203,000 after buying an additional 1,848 shares during the period. Prelude Capital Management LLC grew its stake in Relay Therapeutics by 18.7% in the 3rd quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock valued at $103,000 after buying an additional 3,100 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares during the period. Finally, Deutsche Bank AG raised its holdings in Relay Therapeutics by 3.2% during the 4th quarter. Deutsche Bank AG now owns 123,994 shares of the company’s stock valued at $1,049,000 after acquiring an additional 3,803 shares during the period. 96.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a research report on Monday, January 26th. Finally, Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $6.00 to $13.00 in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Relay Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.57.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.